eli lilly drug - Search News

Hims, Eli Lilly and weight loss

Reuters on MSN · 5h

Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform

By Sneha S K and Puyaan Singh (Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.

Investopedia on MSN · 5h

Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

Seeking Alpha on MSN · 8h

Eli Lilly weight loss therapy added to Hims & Hers platform (update)

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.

Eli Lilly, Risk Factor and Heart Disease

Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)],

Reuters on MSN · 2d

Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.

Seeking Alpha on MSN · 1d

Eli Lilly’s lepodisiran slashes inherited heart disease risk factor by 94% in Phase 2 trial

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically inherited heart disease risk factor in adults with elevated risk taking the highest test dose of the drug candidate.

14hon MSN

Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

12h

Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...

4don MSN

Eli Lilly's Alzheimer's drug rejected in Europe

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

4don MSN

European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

2d

Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

1don MSN

Deadly cholesterol that doesn’t show up on routine tests is slashed by 94% with single dose of new drug

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results